Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Improved Biomarkers and Clinical Outcome Measures, 2017
    Neuron-restricted RNA Profiles in the Plasma of Those with Genetic and Sporadic Parkinson's Disease

    Study Rationale:
    MicroRNAs (miRs) are short RNA molecules (messengers that carry genetic information to DNA) that block protein expression by crossing with hundreds of mRNA targets. Neuron-restricted...

  • Research Grant, 2017
    Phase IIa Safety and Tolerability Trial of Nilotinib in People with Parkinson's Disease

    Study Rationale:
    Previous research has shown higher levels of the c-Abl protein are activated in the brains of people with Parkinson's disease (PD), and studies have linked c-Abl to pathways associated...

  • Target Advancement Program, 2017
    A Novel Role for Galectin Proteins in the Neuronal Response to Alpha-synuclein Invasion

    Study Rationale:
    Galectins proteins (proteins that bind sugar molecules) mediate the cellular response to endocytic (transfer of molecules to cells) vesicles (storage sacks) ruptured by amyloid...

  • Research Grant, 2017
    Standard Operating Procedures for Alpha-synuclein Analysis in Biological Fluids Using a Colorimetric Immunoassay (SYN-SOP)

    Study Rationale:
    The alpha-synuclein protein accumulates in structures called Lewy bodies in the brains of those with Parkinson's disease (PD). These protein clumps are considered to be one of the key...

  • Target Advancement Program, 2017
    Toll-like Receptor Inhibition to Block Alpha-synuclein-induced Pro-inflammatory Signaling and Cytokine Release

    Study Rationale:
    Synucleinopathies, including Parkinson's disease (PD), are a family of central nervous system (CNS) degenerative disorders characterized by alpha-synuclein protein-containing...

  • Improved Biomarkers and Clinical Outcome Measures, 2017
    Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in Parkinson's Disease

    Study Rationale:
    This project will test a new idea for measuring the severity of Parkinson's disease (PD). The brain acts as if it can store each dose of levodopa (L DOPA) for a short period of time...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.